Clinical trial
Integrated Biomarker And Imaging Study - 2
NCT00268996 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00268996 |
|---|---|
| Title | Integrated Biomarker And Imaging Study - 2 |
| Official title | An International, Multicenter, Randomized, Placebo-controlled, Parallel-group, 1 Year Treatment, Integrated Biomarkers and Imaging Study in Subjects With Angiographically Documented Coronary Heart Disease (CHD) to Examine the Effects of the Novel Lipoprotein-associated Phospholipase A2 (Lp-PLA2)… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Atherosclerosis |
| Intervention type | Drug |
| Interventions | SB-480848, SB-480848 matching placebo |
| Enrollment | 336 |
| Start date | Nov 10, 2005 |
| Primary completion | Aug 28, 2007 |
| Completion | Aug 28, 2007 |
| First posted | Dec 23, 2005 |
| Last update posted | Mar 20, 2018 |
| Countries | Austria, Belgium, Czechia, Denmark, France, Germany, Netherlands, Norway, Poland, Spain, Switzerland |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: